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Interleukin-1b Interferes with Epidermal Homeostasis
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Katja Hardt1, Sandra Boehncke2 and Wolf-Henning Boehncke1
Response pathways of the metabolic and the immune system have been evolutionary conserved, resulting in a
high degree of integrated regulation. Insulin is a central player in the metabolic system and potentially also in
the homeostasis of the skin. Psoriasis is a frequent and often severe autoimmune skin disease, clinically
characterized by altered epidermal homeostasis, of which the molecular pathomechanisms are only little
understood. In this study, we have examined a potential role for insulin signaling in the pathogenesis of this
disease. We show that IL-1b is present in high quantities in tissue fluid collected via microdialysis from patients
with psoriasis; these levels are reduced under successful anti-psoriatic therapy. Our results suggest that IL-1b
contributes to the disease by dual effects. First, it induces insulin resistance through p38MAPK (mitogen-
activated protein kinase), which blocks insulin-dependent differentiation of keratinocytes, and at the same time
IL-1b drives proliferation of keratinocytes, both being hallmarks of psoriasis. Taken together, our findings point
toward insulin resistance as a contributing mechanism to the development of psoriasis; this not only drives
cardiovascular comorbidities, but also its cutaneous phenotype. Key cytokines inducing insulin resistance in
keratinocytes and kinases mediating their effects may represent attractive targets for novel anti-psoriatic
therapies.
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INTRODUCTION
Regulating immune responses and metabolism are funda-
mental requirements for survival. Response pathways of the
immune and the metabolic system or pathogen- and nutrient-
sensing systems have been evolutionary conserved, resulting
in a high degree of integrated regulation. The interface of
these systems can be viewed as a central homeostatic mech-
anism, the dysfunction of which can lead to a cluster of
chronic metabolic disorders, such as obesity, type 2 diabetes,
and cardiovascular disease, which constitute the greatest
current threat to global human health (Hotamisligil, 2006).
Insulin is a central player in the metabolic system. Insulin
binding to the insulin receptor (IR) leads to receptor auto-
phosphorylation and recruitment of adaptor molecules such
as IR substrates (IRS 1–6) or Shc (Taniguchi et al., 2006),
which are in turn phosphorylated and serve as binding sites to
nucleate activation of different signaling cascades including
the mitogen-activated protein kinase (MAPK) and phosphoi-
nositide 3-kinase (PI3-K) pathways. These pathways not only
regulate glucose, lipid, and protein metabolism, but also
control mitogenic responses through the control of prolifera-
tion, differentiation, and apoptosis. Insulin signaling is down-
regulated through inhibitory serine phosphorylation of IRS 1,
thus rendering the cells resistant to insulin. Interestingly,
inflammatory mediators, such as cytokines, can induce insulin
resistance through the activation of IRS kinases (Taniguchi
et al., 2006). For example, in endothelial cells, this results in
endothelial dysfunction (Jansson, 2007; Kearney et al., 2008).
Psoriasis is a common, highly stigmatizing chronic inflam-
matory skin disease that presents with sharply demarcated,
red scaly plaques on the skin (Nestle et al., 2009). There is
increasing awareness that psoriasis is more than ‘‘skin deep’’
and that it has important systemic manifestations (Nestle
et al., 2009). Of emerging significance is the relationship
between psoriasis and cardiovascular diseases (Boehncke
et al., 2010), explaining much of the increased mortality
among psoriasis patients (Gelfand et al., 2007). We and
others have recently shown that psoriasis patients exhibit
signs of insulin resistance and that this ‘‘pre-diabetic’’ metabolic
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state is caused at least in part by the severity of the psoriatic
inflammation and may lead to the above-mentioned comor-
bidities (Boehncke et al., 2007; Cerman et al., 2008).
Insulin has a role in the homeostasis of the skin. The IR and
all downstream signaling cascades are expressed in the skin
and can be activated by insulin (Wertheimer et al., 2000).
Several reports suggest that severe insulin resistance of
resident wound cells contributes to disturbed cellular
dynamics in chronic wounds and that insulin participates
in tissue repair (Goren et al., 2006, 2009). Notably,
epidermal changes seen in psoriasis show remarkable
similarities with wound healing, including hyperprolifera-
tion and altered differentiation of keratinocytes (Bovenschen
et al., 2005).
Although IR signaling is well understood, little is known
about a potential role of insulin in the development and
maintenance of a psoriatic plaque, or the intracellular
signaling processes that integrate insulin- and cytokine-
mediated cellular decisions at the site of lesional psoriatic
skin. At the cellular and molecular level, striking similarities
between atherosclerotic and psoriatic plaques have been
described (Spah, 2008). Therefore, we asked whether similar
mechanisms namely insulin resistance could contribute to
the epidermal phenotype in psoriasis. Here we show that IL-
1b can readily be detected in tissue fluid from psoriatic
plaques, and that it induces insulin resistance in keratino-
cytes in vitro. This results in altered keratinocyte differentia-
tion, indicating that IL-1b interferes with IR signaling at
the intersection of differentiation and proliferation. Our
observations suggest that insulin resistance might be a
modulating mechanism that contributes to the pathology
seen in psoriasis both at the endothelial and the epithelial
level and point toward potential novel targets for anti-
psoriatic therapy.
RESULTS
IL-1b tissue levels reflect the clinical course of psoriatic plaques
IL-1b, a cytokine that induces insulin resistance in other
tissues and plays a crucial role in the pathogenesis of
psoriasis (Sanmiguel et al., 2009; Renne et al., 2010), was
analyzed in tissue fluid from lesional and non-lesional skin of
patients suffering from psoriasis, collected through micro-
dialysis. We found high levels of IL-1b in the psoriatic plaque
(13,527–35,460 pgml1) compared with non-lesional skin
(5,873–9,080 pgml1) before beginning anti-inflammatory
therapy. The amelioration of the skin symptoms was
paralleled by an average IL-1b reduction of 80% at the
site of the former plaque (Figure 1). Thus, IL-1b was shown
to be upregulated in lesional psoriatic skin, and its con-
centration is reduced under effective systemic anti-inflam-
matory therapy.
IL-1b induces insulin resistance in human keratinocytes via
p38MAPK
IL-1b is able to confer insulin resistance in metabolically
active tissues. Therefore, we examined whether IL-1b can
confer similar effects in human keratinocytes. After 48 hours
of IL-1b treatment, we observed a dose-dependent reduction
in protein kinase B (PKB) S473 phosphorylation up to 50%
after insulin stimulation in either HaCaT (Figure 2a and b) or
normal human keratinocytes (NHKs) (Figure 2c). This result
was confirmed by a reduced phosphorylation pattern of PKB
substrate proteins under conditions of chronic IL-1b exposure
(Supplementary Figure S1 online). In contrast, neither tumor
necrosis factor (TNF)-a (Figure 2a) nor several other
cytokines, including IL-12, IL-17, IL-22, and IL-23 (data not
shown), were able to suppress this phosphorylation step.
Significantly, insulin-dependent activation of Erk1 was not
modulated by the presence of IL-1b, indicating that this
arm of signaling from the IR is still active (Figure 2b). This
effect is specific to insulin, as chronic IL-1b exposure does
not severely influence the sensitivity to insulin-like growth
factor-1 or epidermal growth factor in HaCaT or NHK cells
(Figure 2d).
Insulin resistance is mediated by inhibitory serine phos-
phorylation of IRS 1 and serves as a physiological negative
feedback mechanism in insulin signaling. Metabolic and
inflammatory stress may hijack this mechanism by activating
kinases that are known to phosphorylate IRS 1 such as
p38MAPKa (Schinner et al., 2005; Boura-Halfon and Zick,
2009). As a crucial role for p38MAPK in the pathogenesis of
psoriasis was described (Funding et al., 2006; Johansen et al.,
2006) and p38MAPK is suggested as a novel anti-psoriatic
target (Pettus and Wurz, 2008; Soegaard-Madsen et al.,
2010), we asked whether this kinase mediates IL-1b-induced
insulin resistance in keratinocytes. Therefore, we blocked
p38MAPK by a chemical inhibitor (Figure 2c and e) or by
small interfering RNA (siRNA)-mediated knockdown (Figure
2f) and found complete restoration of insulin-dependent PKB
phosphorylation in HaCaT cells. In NHK cells, only partial
rescue of insulin sensitivity could be detected (Figure 2c).
These results document a role of p38MAPK in mediating
insulin resistance in keratinocytes.
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Figure 1. Dermal IL-1b levels are paralleled by the clinical amelioration of
the disease. A target psoriatic lesion (PP) and non-lesional skin (PN) was
defined in three patients (Pat) with severe plaque-type psoriasis, from which
tissue fluid was taken by microdialysis before (w0) and 12 weeks (w12) into
systemic anti-inflammatory therapy with fumaric acid esters. The
concentration of IL-1b in the tissue fluid was determined and normalized to
the values measured at w0 in the plaque (PP w0).
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Insulin resistance interferes with the differentiation of
keratinocytes
Altered proliferation and differentiation are hallmarks of
psoriasis; therefore, we examined the functional conse-
quences of insulin and IL-1b signaling on these properties
in keratinocytes. First, we assessed proliferation by means of
5-bromo-20-deoxyuridine incorporation, and found that
insulin induces proliferation of keratinocytes (Figure 3a),
which was unaffected by the addition of increasing concen-
trations of IL-1b (Figure 3b). At the same time, IL-1b by itself
leads to enhanced proliferation (Figure 3b). No additive effect
of insulin and IL-1b on proliferation could be measured. This
can be explained by the induction of insulin resistance by
IL-1b, resulting in the ablation of insulin-induced proliferation,
whereas only the IL-1b–dependent effect remains. Insulin
also induced differentiation of HaCaT and NHK cells, as mea-
sured by the expression of keratin 10 and involucrin at the RNA
(data not shown) and protein level (Figure 3c). We then asked
whether IL-1b could also prevent insulin-dependent differentia-
tion. Although IL-1b alone did not have an effect on the
induction of differentiation, IL-1b blocked insulin-driven
differentiation as measured by the expression of keratin
10 and involucrin (Figure 3c and d). In summary, we could
show dual effects of IL-1b action by (i) inducing proliferation
and (ii) rendering keratinocytes insulin resistant, and thus
blocking insulin-mediated effects such as differentiation.
a
Insulin
Insulin
Insulin
P-PKB (S473)
P-PKB (S473)
P-PKB (S473)
P-PKB (S473)
P-Erk1 (T202/Y204)
PKB
PKB
PKB
PKB
ng ml–1 lL-1β
Insulin
Insulin
P-PKB (S473)
P-PKB (S473)
PKB
PKB
ng ml–1 lL-1β
Insulin
ng ml–1 lL-1β
Insulin
ng ml–1 lL-1β
ng ml–1 lL-1β
10
1
IL-1βTNFα
IL-1β
IL-1β
siRNA
IL-1β
R
el
. P
KB
ph
os
ph
or
yla
tio
n
R
el
. P
KB
ph
os
ph
or
yla
tio
n
b c
d
e
f
20
– + – + – +
– + – +– +– +– +
–
–
+
– + – + – + – + – +
––
– – –
– –
–
+ + + +
++++
–+
– +
– + – +
– +
***
**
– +– + – +– +– +– +
100
20 100
20 100 20 100
Ins
100
10 100 10 100
SB203580
SB203580
Control p38MAPK
p38MAPK
β-Actin
200
HaCaT
HaCaT
HaCaT
HaCaT
HaCaT
NHK
NHK
0.5
0
1
0.5
0
IGF EGF – Ins IGF – –Ins IGF Ins IGFEGF
Figure 2. IL-1b-induced insulin resistance is mediated by p38MAPK. (a–c) Starved HaCaT or normal human keratinocyte (NHK) cells were treated with
20 ngml1 tumor necrosis factor-a (TNF-a) or IL-1b, or the indicated concentrations for 48 hours, followed by 10minutes of stimulation with 100 nM insulin.
Four blots similar to the ones presented (b, c) were quantified using the ImageJ software. *Po0.001; **Po0.05. (d) Starved HaCaT or NHK cells were treated for
48 hours with 100 ngml1 IL-1b and stimulated with 100 nM insulin (Ins), 10 ngml1 insulin-like growth factor-1 (IGF-1), or 50 ngml1 epidermal growth factor
(EGF) for 10minutes. In (c, e), starved cells were treated with IL-1b and 10 mM SB203580 for 48 hours, followed by 10minutes of insulin stimulation. (f) Small
interfering RNA (siRNA)-transfected HaCaT cells were starved and treated with 100 ngml1 IL-1b (48 hours) and 100 nM insulin (10minutes). Immunoblots
were performed with the indicated phospho-specific or total protein antibodies. MAPK, mitogen-activated protein kinase; PKB, protein kinase B; P-PKB,
phosphorylated PKB.
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PKB is hyperactivated in psoriatic plaques
The pathophysiological relevance of our in vitro observations
was assessed by examining the activation of the insulin
pathway in skin samples from patients suffering from plaque-
type psoriasis, and also compared these with normal skin of
healthy donors. Interestingly, PKB is highly activated in all
epidermal layers of lesional psoriatic skin, except the basal
layer (Figure 4a and d). Higher-magnification images (Figure
4d) and co-staining with markers for intermediate differentia-
tion (keratin 1/10) (Supplementary Figure S2a online)
localized phosphorylated PKB in the suprabasal and granular
layers in the psoriatic plaque, while PKB is not activated in
the basal layer (Figure 4d, Supplementary Figure S2c, e
online; co-staining with Ki-67). In contrast, non-lesional
psoriatic skin from the same donors (Figure 2b and e), as well
as skin from healthy controls (Figure 4c and f), stained only
weakly positive in the upper epidermis (Figure 4b, c, e, and f).
At the same time, PKB is expressed throughout the epidermis
of lesional psoriatic skin (Figure 4g), which is particularly
strong in dermal microvessels (Supplementary Figure S3
online; co-staining with CD31). In contrast, PKB is only
weakly expressed in non-lesional psoriatic or healthy skin
(Figure 4h and i). In summary, we found evidence for PKB
hyperactivation in psoriatic plaques in situ. Western blot
analysis confirmed hyperactivation of PKB in the psoriatic
lesion (Figure 4j and k). These findings were at first
unexpected, as our in vitro data suggested that prolonged
stimulation of keratinocytes with IL-1b should result in PKB
inhibition. Nevertheless, keratinocytes from psoriatic lesions
are insulin resistant, as phosphorylation of PKB cannot further
be increased by insulin stimulation, whereas in non-lesional
keratinocytes from the same patient PKB is sensitive to insulin
stimulation (Figure 4k). This finding is supported by the fact
that IRS 1 shows inhibitory serine phosphorylation in lesional
skin. Activation of inflammatory cascades in the lesion is
reflected by activation of c-Jun N-terminal kinase (JNK) and
activating transcription factor 2 (Figure 4k) and p38MAPK
(Figure 4j and k; Supplementary Figure S4 online). However,
some patients also showed the activation of p38MAPK in
non-lesional skin (Figure 4j, k, patients 1 and 3; Supplemen-
tary Figure S4b online). All these kinases might be able
to confer insulin resistance by phosphorylating IRS 1. In
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Figure 3. Insulin resistance interferes with differentiation of keratinocytes. (a, b) HaCaT cells were starved, stimulated with insulin or IL-1b for 48 hours, and
proliferation was measured by means of 5-bromo-20-deoxyuridine (BrdU) incorporation. The graphs represent (a) five or (b) seven independent experiments, and
error bars represent the mean±SD. *Pp0.001; **Po0.05. (c) HaCaT or normal human keratinocyte (NHK) cells were treated with 100 nM insulin (Ins),
100 ngml1 IL-1b, or 3mM CaCl2 for 6 days, and the expression of keratin 10 (K10), involucrin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and actin
was assessed by immunoblotting. (d) HaCaT cells were treated with IL-1b and insulin or 3mM CaCl2. After 8 days, intracellular K10 expression was measured by
flow cytometry. The graph represents mean values of four independent experiments, and error bars represent the mean±SD of these experiments.
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Figure 4. Protein kinase B (PKB) is hyperactivated in psoriatic skin. Punch biopsy sections from (a, d, g) diseased, (b, e, h) non-lesional skin of a psoriasis
vulgaris patient, or a (c, f, i) healthy donor were stained for (a–f) phosphorylated-PKB (P-PKB) S473 or (g–i) PKB. (d–f) Higher-magnification images of the
same slide as presented in a–c. Nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI) (blue). Overlay images are shown. Bar¼ 50mm. (j) Epidermal
lysates were prepared from lesional (PP) or non-lesional skin (PN) of psoriasis vulgaris patients and probed with the indicated antibodies. (k) The epidermis
from lesional (PP) or non-lesional psoriatic skin (PN) was split in half, and one part was stimulated with insulin for 30minutes. Lysates were prepared and
probed with the indicated antibodies. ATF2, activating transcription factor 2; IRS1, insulin receptor substrates; JNK, c-Jun N-terminal kinase; MAPK,
mitogen-activated protein kinase; Pat, patient; SAPK, stress-activated protein kinase.
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summary, psoriatic keratinocytes are resistant to insulin
stimulation; however, hyperactivation of PKB must me attri-
buted to a different mechanism.
Short-term IL-1b exposure strongly activates PKB via PI3-K and
p38MAPKa in keratinocytes
Next, we asked which mediator in psoriasis is able to activate
PKB. We found that short-term IL-1b and TNF-a treatment not
only activated pro-inflammatory pathways involving phos-
phorylation of JNK, IKKa, and p38MAPKa, but also induced
strong transient activation of PKB (Figure 5a and b). By using
chemical inhibitors of different signaling kinases, we found
that inhibiting PI3-K with LY294002 or Wortmannin abol-
ished IL-1b–dependent activation of PKB (Figure 5c), indicat-
ing that the IL-1b receptor signals toward PKB via PI3-K.
Interestingly, chemical inhibition of p38MAPK or JNK or
siRNA-mediated knockdown of p38MAPKa blocked the
activation of PKB by IL-1b (Figure 5c and d). In contrast,
inhibition of the mammalian target of rapamycin complex
with rapamycin did not alter the IL-1b–dependent induction
of PKB (Figure 5c). Therefore, we assume that binding of IL-
1b to its cognate receptor activates pro-inflammatory kinases
such as p38MAPKa or JNK, which in turn activate PKB, a yet
unknown mechanism. This interplay takes place either at the
level of PI3-K or upstream. This IL-1b–dependent activation
of PKB might represent the pathway through which IL-1b
mediates its proliferative effects.
In summary, we could show that insulin is a prerequisite
for proper formation of the epidermal structure by participat-
ing in keratinocyte differentiation. IL-1b interferes with this
mechanism and contributes to the pathogenesis of psoriasis
with dual effects. On one hand, it blocks insulin-induced
differentiation by means of insulin resistance via p38MAPK.
On the other hand, IL-1b activates PKB, which induces
proliferation. Both mechanisms are typical epidermal
changes that characterize a psoriatic lesion.
DISCUSSION
The key finding of this study is that IL-1b, a prototypic pro-
inflammatory cytokine, induces insulin resistance in kerati-
nocytes, which in turn alters their pattern of proliferation and
differentiation. There is increasing evidence that insulin plays
an important role in sustaining the physiology of the skin
(Wertheimer et al., 2000, 2001; Goren et al., 2006), although
the exact function of insulin signaling remains controversial.
To our knowledge, it is previously unreported that insulin is
able to drive differentiation of human keratinocytes, a
mechanism that is important for healthy skin physiology.
Former reports show that insulin enhances Ca2þ -induced
differentiation of murine keratinocytes (Wertheimer et al.,
2000). Our results are in line with in vivo experiments, which
show that IR knockout mice have normal skin physiology, but
disturbed keratinocyte differentiation (Wertheimer et al.,
2001). Interestingly, inactivation of epidermal insulin signal-
ing results in a hypomorphic epidermis with no changes in
proliferation or differentiation, likely through compensation
from the dermal compartment (Stachelscheid et al., 2008).
We assume that insulin mediates differentiation via PKB,
which can also be activated by Ca2þ , a stimulus for HaCaT
differentiation (Calautti et al., 2005).
A central role for IL-1b has long been established in
psoriasis (Groves et al., 1996; Renne et al., 2010) by regu-
lating the expression of T-cell–targeting chemokines that
contribute to T-cell extravasation (Sanmiguel et al., 2009). To
our knowledge, we report for the first time that IL-1b is
elevated in the tissue fluid of psoriatic plaques and that the
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Figure 5. IL-1b activates protein kinase B (PKB) via phosphoinositide
3-kinase (PI3-K), c-Jun N-terminal kinase (JNK), and p38MAPK. (a, b)
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(siRNA), serum starved, and stimulated with 100 ngml1 IL-1b for 30minutes.
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blotting with the indicated antibodies. Contr, control; P-IKK, phosphorylated-
IkB kinase; MAPK, mitogen-activated protein kinase; Pat, patient; P-PKB,
phosphorylated-PKB; SAPK, stress-activated protein kinase.
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amelioration of the skin symptoms during the course of sys-
temic anti-inflammatory therapy is paralleled by the reduc-
tion of soluble IL-1b in the epidermis. Our results are in
accordance with the finding that IL-1b mRNA is upregulated
in lesional skin of psoriatic patients (Debets et al., 1997).
Several reports show that IL-1b is able to confer insulin
resistance in adipocytes (He et al., 2006; Jager et al., 2007),
although the presence of insulin resistance in non-metabolic
cells is not as established. Only TNF-a was shown to
contribute to impaired insulin signaling during wound
healing in diabetic mice (Goren et al., 2006). We demon-
strated that long-term IL-1b treatment induces insulin
resistance in keratinocytes, which is mediated by p38MAPK.
This characteristic of p38MAPK, which to our knowledge is
previously unreported, is supported by the fact that p38MAPK
is hyperphosphorylated in most psoriatic lesions and seems to
have an important role in the pathogenesis of psoriasis
(Johansen et al., 2006; Yu et al., 2007). At the same time,
p38MAPK inhibitors are emerging as new therapeutic tools
for the treatment of chronic inflammatory disorders (Gold-
stein et al., 2010). Therefore, our findings suggest a yet
unreported mechanism by which p38MAPK contributes to
the pathogenesis of psoriasis.
Importantly, we have shown that IL-1b–induced insulin
resistance blocks insulin-dependent differentiation while
proliferation persists. This most likely represents a mechanism
by which IL-1b contributes to the pathogenesis of a psoriatic
plaque. Unexpectedly, immunohistology data showed that
PKB is hyperactivated in the psoriatic plaque. This result was
initially surprising, as our in vitro data had indicated that
chronic IL-1b exposure downregulates PKB by means of
insulin resistance. Gupta and Khandelwal (2004) showed a
similar mechanism in hepatocytes, in which short-term TNF-
a and insulin treatment had an additive effect on phosphor-
ylation of PKB, whereas long-term pretreatment with TNF-a
reduced insulin-stimulated phosphorylation of PKB. We
found that short-term treatment with IL-1b or TNF-a treatment
activated the PI3-K pathway, leading to the activation of PKB
and induction of proliferation, which is consistent with the
finding that TNF-a activates PKB in keratinocytes via atypical
PKC (Faurschou and Gniadecki, 2008). Despite this high
activation status, psoriatic keratinocytes are resistant to
further stimulation with insulin and show inhibitory IRS
phosphorylation, arguing that insulin resistance might con-
tribute to the psoriatic phenotype.
Interestingly, activated PKB was only detected in supra-
basal layers of psoriatic lesions, but not in the basal Ki-67-
positive layer that represents dividing cells. This may be
explained either by psoriatic keratinocytes that keep their
proliferative pathways turned on even after leaving the basal
layer or by the role of PKB in preventing cellular apoptosis,
which contributes to the fast maturation process of psoriatic
keratinocytes (Calautti et al., 2005; Hosotani et al., 2008).
Thus, we propose a model (Figure 6) in which PKB has a
central role at the intersection of proliferation and differ-
entiation. Under physiological conditions, insulin seems to
primarily regulate the differentiation of keratinocytes, as
active PKB could only be detected in terminally differentiated
cells in non-lesional or healthy skin. During long-term
exposure to inflammatory cytokines such as IL-1b, insulin
resistance via p38MAPK is induced and thereby blocks PKB-
mediated differentiation. At the same time, IL-1b is able to
activate PKB via a different set of kinases such as JNK or
p38MAPK, which results in induction of proliferation.
We assume that under these conditions PKB is organized
in a signalosome that preferentially induces proliferative
pathways, whereas the insulin-dependent and differentiation-
inducing functions are shut off by means of insulin
resistance.
Systemic insulin resistance due to inflammation is currently
also thought to contribute to an increased cardiovascular risk
in patients with severe psoriasis (Boehncke et al., 2007,
2010), and its pathogenetic role in atherosclerosis is well
established (Semenkovich, 2006). Our observations provide
evidence for a role of dermal insulin resistance during the
development of the psoriatic phenotype as well. Therefore,
treatment strategies aimed to reverse insulin resistance may
therefore prove to be effective not only with regard to
controlling the psoriatic rash, but also to reduce the patients’
increased cardiovascular risk.
MATERIALS AND METHODS
Chemicals and antibodies
All chemicals were purchased from Sigma (Steinheim, Germany),
unless stated otherwise. All phospho-specific and corresponding
pan antibodies were from Cell Signaling Technology (Frankfurt,
Germany). Actin antibody was from Sigma, keratin 10 and
involucrin from Abcam (Cambridge, MA), and keratin 1/10 from
Millipore (Billerica, CA). GAPDH antibody was from Santa Cruz
IRS
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IL-1β
Insulin
p38MAPK
ProliferationDifferentiation
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PKB/
Akt
Figure 6. IL-1b blocks insulin-mediated differentiation and induces
proliferation of keratinocytes. Under healthy conditions, insulin regulates—
via the phosphoinositide 3-kinase (PI3-K)/protein kinase B (PKB) pathway—
the equilibrium between proliferation and differentiation of keratinocytes, a
prerequisite for the formation of the epidermal structure. Under conditions of
chronic inflammation, such as psoriasis, high dermal IL-1b levels activate
p38MAPK, which induces insulin resistance by serine phosphorylation of IRS,
leading to blockade of differentiation. At the same time, IL-1b–induced
activation of p38MAPK and JNK leads to proliferation via the PI3-K
pathway. Therefore, both IL-1b–mediated effects might represent novel
pathomechanisms that contribute to the development of the psoriatic plaque.
IRS, insulin receptor; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated
protein kinase.
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(Heidelberg, Germany), CD31 antibody was from DAKO (Hamburg,
Germany), and Ki-67 from Novus Biologics (Cambridge, UK). For
FACS-based measurement, antibodies were fluorescently labeled
using the Lightning Link Kit from Biomol (Hamburg, Germany).
Rapamycin, SB203580, SP600125, Wortmannin, and LY294002
were from Calbiochem (Darmstadt, Germany).
Microdialysis and determination of IL-1b levels
Three patients with severe plaque-type psoriasis signed written
informed consent to undergo microdialysis before therapy initiation,
as well as 12 weeks into the treatment. Two catheters (CMA, Solna,
Sweden) with permeable membranes were placed into the skin,
one into a psoriatic plaque and one into non-lesional skin, and
microdialysis was continuously performed for 6 hours. The amount
of IL-1b was determined in a fluorescent bead immunoassay
(BenderMedSystems, Vienna, Austria). This study was approved by
the local ethics committee of the Clinic of the Goethe-University
(316/06); the Declaration of Helsinki protocols were followed.
Cell culture and conditions
The spontaneously immortalized human keratinocyte cell line
(HaCaT) (Prof Fusenig, DKFZ, Heidelberg, Germany) was cultured
in carbonate-buffered Hank’s medium with 10% fetal calf serum
(Biochrom, Berlin, Germany), 0.35 g/l glutamine, and 1% penicillin/
streptomycin solution (Invitrogen, Karlsruhe, Germany). NHK cells
were isolated from human juvenile foreskin and cultured in
keratinocyte growth medium (Promo Cell, Heidelberg, Germany)
at 37 1C in 5% CO2 atmosphere.
Western immunoblotting
Cells were lysed in lysis buffer (Cell Signaling Technology),
normalized, subjected to SDS-PAGE, and blotted onto polyvinyli-
dene difluoride membranes. After blocking in 5% milk/Tris-buffered
saline and Tween 20 (50mM Tris-HCl (pH 7.5), 150mM NaCl, 0.1%
Tween 20), membranes were probed with the indicated antibodies
and visualized with horseradish peroxidase–conjugated secondary
antibodies using LumiGlo reagent (Cell Signaling Technology). For
western blots of skin samples, 6-mm punch biopsies were separated
into the epidermis and dermis with thermolysin and lysed.
Representative blots of at least four experiments are shown.
Differentiation of keratinocytes
HaCaT or NHK cells were seeded in Ca2þ -free medium and induced
with Ca2þ or insulin. The medium was changed every 48 hours.
Cells were harvested and either lysed and subjected to western
blotting or analyzed by flow cytometry. For the latter, cells were
fixed with Cytofix (BD, Heidelberg, Germany), followed by permea-
bilization with Perm Buffer III (BD) and stained with phycoerythrin-
labeled keratin 10 antibody. As an internal control, cells were
stained with a allophycocyanin-labeled anti-actin antibody. For
analysis, the geometric mean of unstained cells was subtracted from
the geometric mean of stained cells of the same sample.
Proliferation of keratinocytes
Quantification of cell proliferation was determined by 5-bromo-20-
deoxyuridine incorporation using a colorimetric cell proliferation
ELISA (Roche, Mannheim, Germany). The assay was carried out
according to the product instruction manual. Briefly, 24 hours after
seeding, cells were starved in serum-free medium overnight and
stimulated for 48 hours. For the last 18 hours, cells were grown in the
presence of 5-bromo-20-deoxyuridine.
siRNA-mediated knockdown
Stealth siRNA directed against p38MAPKa (50-CCAAAUUCUCC
GAGGUCUAAAGUAU-30) and BLOCK-IT Negative Control was
synthesized by Invitrogen. siRNAs were transfected using Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s instructions.
Briefly, 80 pmol siRNA duplexes (final concentration 66nM) and 4ml
Lipofectamine 2000 were diluted separately in OptiMEM-I (Invitro-
gen), mixed, and added to the cells.
Immunohistochemistry
Punch biopsies from lesional and non-lesional skin of three patients
with severe psoriasis before initiation of therapy, as well as from
healthy-looking skin of two individuals with non-inflammatory skin
diseases, were taken after written informed consent. These were cut
into 8-mm cryosections and paraformaldehyde-fixed before staining
with the indicated antibodies and fluorescent labeled secondary
antibodies. Nuclei were stained with 40,6-diamidino-2-phenylin-
dole. Confocal images were generated using a Zeiss LSM510
microscope. This study was approved by the local ethics committee
of the Clinic of the Goethe-University (316/06); the Declaration of
Helsinki protocols were followed.
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